NRAS and melanoma: Taken together, these results indicate that the combination of BETi/MEKi perturbs the cell cycle machinery and activates apoptotic signaling in NRAS‐mutant melanoma cells in part by synergistically downregulating the PHD‐type zinc finger domain containing transcription factor TCF19.